Related Experiment Video
Updated: Aug 2, 2026
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
13.3K
Development and evaluation of a CRISPR-Cas13a system-based diagnostic for hepatitis E virus
Manyu Li1, Qiyu He2, Tingting Li3
1Division I of In Vitro Diagnostics for Infectious Diseases, Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing, P.R. China.
Clinical Chemistry and Laboratory Medicine
|December 28, 2023
Summary
A new CRISPR-Cas13a system offers a rapid and accessible method for detecting Hepatitis E virus (HEV) RNA. This advanced diagnostic tool provides high sensitivity and specificity, improving HEV infection diagnosis, especially in resource-limited settings.
Area of Science:
- Molecular biology
- Virology
- Biotechnology
Background:
- Hepatitis E virus (HEV) is a major global cause of acute viral hepatitis.
- Current HEV RNA detection methods like PCR are often time-consuming, expensive, and have limited reach, particularly in low-income regions.
- There is a need for simpler, more accessible, and efficient diagnostic tools for HEV infection.
Purpose of the Study:
- To develop and evaluate a novel, accessible HEV RNA detection method utilizing the CRISPR-Cas13a system.
- To assess the sensitivity, specificity, and genotype detection capabilities of the developed CRISPR-Cas13a assay.
- To compare the performance of the CRISPR-Cas13a assay against the established RT-qPCR method.
Main Methods:
- A CRISPR-Cas13a-based detection system was engineered for HEV RNA.
- The assay's performance was evaluated using 265 samples (89 positive, 176 negative).
- Sensitivity, specificity, cross-reactivity, genotype coverage (HEV1-4), and comparison with RT-qPCR were assessed.
Main Results:
- The CRISPR-Cas13a fluorescence and strip assays demonstrated limits of detection of 12.5 IU/mL and 200 IU/mL, respectively.
- The assay showed no cross-reactivity with other common viruses and bacteria.
- High positive predictive agreements (98.9% for fluorescence, 91.0% for strip) and 100% negative predictive agreement were observed compared to RT-qPCR.
Conclusions:
- A rapid, convenient, sensitive, and specific HEV RNA detection method based on the CRISPR-Cas13a system has been successfully established.
- This novel assay offers a promising alternative for HEV infection diagnosis.
- The developed system enhances diagnostic accessibility, particularly in resource-limited settings.
